INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

People assigned to a diet, food or program and measured.

2,768 studies · page 3 of 116

2022 / 8-week single-blinded randomized controlled trial

In people with cardiovascular risk factors, dried purple-black barberry consumption significantly lowered plasma lipids and CRP compared to placebo.

An 8-week single-blind randomized controlled trial evaluated the effects of 10 g/day dried barberry versus placebo in 84 participants with cardiovascular risk factors. Body weight, BMI, physical activity, and dietary intake did not differ between groups. After adjusting for baseline values, the barberry group showed significant decreases compared to placebo in TG (p < 0.001), TC (p = 0.011), LDL-C (p = 0.015), sd-LDL-C (p = 0.019), non-HDL-C (p = 0.004), TC/HDL-C (p = 0.039), and CRP (p = 0.020).

Emamat H, Zahedmehr A, Asadian S, et al. BMC Complement Med Ther, 2022. PMID 35255880

2022 / Randomized, double-blind, placebo-controlled, 2-by-2 factorial trial

Cocoa extract supplementation did not significantly reduce total cardiovascular events in older adults, but reduced cardiovascular death by 27%.

The COSMOS trial randomized 21,442 older US adults to a cocoa extract supplement (500 mg flavanols/d, including 80 mg epicatechin) or placebo for a median follow-up of 3.6 years. Cocoa extract did not significantly reduce confirmed total cardiovascular events (410 vs 456 participants; HR: 0.90; 95% CI: 0.78, 1.02; P = 0.11). However, secondary endpoints showed a significant reduction in cardiovascular death (HR: 0.73; 95% CI: 0.54, 0.98), while per-protocol analysis indicated a lower risk of total events (HR: 0.85; 95% CI: 0.72, 0.99). All-cause mortality (HR: 0.89; 95% CI: 0.77, 1.03) and other individual endpoints were not significantly different, and no safety concerns were observed.

Sesso HD, Manson JE, Aragaki AK, et al. Am J Clin Nutr, 2022. PMID 35294962

2022 / Randomized controlled trial

Consuming 40 g of brown or golden flaxseed daily for 12 weeks reduced intestinal permeability and endotoxemia in perimenopausal overweight women.

Thirty perimenopausal overweight women were divided into a control group, brown flaxseed group, and golden flaxseed group, with the intervention groups consuming 40 g of flaxseed daily for 12 weeks. Intestinal permeability was significantly reduced in the flaxseed groups, with a smaller delta of lactulose/mannitol ratio (p ≤ 0.05). LPS levels were reduced in both flaxseed groups, while LDL decreased in the golden flaxseed group (p ≤ 0.05). Flaxseed consumption did not change oxidative stress markers or fasting glycaemia.

Sant'Ana CT, Amorim AD, Gava AP, et al. Int J Food Sci Nutr, 2022. PMID 35311432

2022 / Randomized, double-blind crossover trial

Intraduodenal quinine stimulated gut and pancreatic hormones and lowered glucose more than intragastric quinine in healthy men and women.

In a randomized, double-blind crossover study, 14 men and 14 women received 600 mg quinine hydrochloride (QHCl) via intragastric (IG) or intraduodenal (ID) administration on separate occasions. Suppression of ghrelin (P = 0.006), stimulation of cholecystokinin (P = 0.030), peptide YY (P = 0.017), GLP-1 (P = 0.034), insulin (P = 0.024), glucagon (P = 0.030), and pyloric pressures (P = 0.050), as well as glucose lowering (P = 0.001), were greater after ID-QHCl than IG-QHCl. In addition, insulin stimulation (P = 0.021) and glucose reduction (P = 0.001) were greater in females than males, while other measured hormones and pressures showed no sex differences.

Rezaie P, Bitarafan V, Rose BD, et al. J Clin Endocrinol Metab, 2022. PMID 35325161

2022 / Randomized controlled trial extension

One year after stopping semaglutide and lifestyle intervention, participants regained two-thirds of their prior weight loss.

In the STEP 1 trial extension, 327 participants who completed 68 weeks of once-weekly semaglutide 2.4 mg or placebo plus lifestyle intervention were followed for 52 weeks after discontinuing all treatments. Mean weight loss from week 0 to 68 was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following withdrawal, semaglutide participants regained 11.6 percentage points (SD: 7.7) of lost weight by week 120, yielding a net weight loss of 5.6% (SD: 8.9%) from week 0 to 120, while placebo participants regained 1.9 percentage points (SD: 4.8; net loss 0.1%). Cardiometabolic improvements seen at week 68 with semaglutide reverted toward baseline at week 120 for most variables.

Wilding JPH, Batterham RL, Davies M, et al. Diabetes Obes Metab, 2022. PMID 35441470

2022 / Placebo-controlled, randomized, double-blind, parallel-group trial

Oral administration of 250 mg/day of nicotinamide mononucleotide for 12 weeks was safe and significantly increased whole blood NAD+ levels in healthy subjects.

In a randomized, double-blind trial, 30 healthy volunteers received either 250 mg/day of NMN (n = 15) or a placebo (n = 15) for 12 weeks. Oral NMN caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed. Whole blood NAD+ and nicotinic acid mononucleotide (NAMN) levels were significantly increased after NMN administration, while NMN levels themselves were not. Additionally, the increase in NAD+ was strongly correlated with pulse rate prior to NMN administration.

Okabe K, Yaku K, Uchida Y, et al. Front Nutr, 2022. PMID 35479740

2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial

Celery seed extract was safe and improved blood pressure, fasting blood sugar, lipid profiles, and liver/kidney markers in hypertensive patients.

In a triple-blind, placebo-controlled crossover trial, 51 hypertensive patients received either celery seed capsules (1.34 g extract daily) or placebo for 4 weeks alongside usual medications. Celery seed extract was safe, reduced blood pressure, and decreased FBS from 108.53 to 97.96 mg/dL (p < 0.01). Significant reductions were seen in BUN (3.43 mg/dL), SCr (0.075 mg/dL), SGPT (4.08 U/L), SGOT (3.03 U/L), TC (16.37 mg/dL), TG (16.22 mg/dL), and LDL (11.84 mg/dL), along with an increase in HDL of 2.52 mg/dL (all p < 0.05 or p < 0.001). No significant changes were found in blood cells or serum electrolytes; the study was limited by a small sample size.

Shayani Rad M, Moohebati M, MohammadEbrahimi S, et al. Inflammopharmacology, 2022. PMID 35536382

2022 / Randomized, double-blind, placebo-controlled crossover trial

Three months of resveratrol supplementation did not reduce hormonal migraine burden, disability, or improve quality of life.

A randomized, double-blind, placebo-controlled crossover trial evaluated the effect of consuming 75 mg of resveratrol twice daily for three months versus placebo in 62 hormonal migraineurs. Outcomes included the hormonal migraine burden index (HMBI), Headache Impact Test-6™, Migraine Disability Assessment, and Migraine-Specific Quality of Life. No significant differences were observed between resveratrol and placebo for HMBI (p = 0.895) or any secondary disability and quality-of-life measures.

Dzator JSA, Howe PRC, Coupland KG, et al. Nutrients, 2022. PMID 35565731

2022 / Randomized, triple-blind, placebo-controlled, cross-over clinical trial

Celery seed extract significantly reduced systolic, diastolic, mean arterial, and pulse pressure in patients with hypertension.

A randomized, triple-blind, placebo-controlled crossover trial evaluated the effect of 4 celery seed extract capsules (1.34 g/day) versus placebo taken daily for 4 weeks in 52 hypertensive patients. In the celery group, systolic blood pressure decreased from 141.2 ± 5.91 to 130.0 ± 4.38 mmHg (p < .001) and diastolic blood pressure decreased from 92.2 ± 5.74 to 84.2 ± 4.87 mmHg (p < .001). Mean arterial blood pressure also changed from 108.5 ± 5.76 to 99.5 ± 4.66 mmHg (p < .001), and pulse pressure decreased from 49.0 ± 6.21 to 45.8 ± 6.01 mmHg (p < .01), whereas no significant changes occurred with placebo (p > .05). No significant side effects were reported in the celery group compared to placebo (p > .05).

Shayani Rad M, Moohebati M, Mohajeri SA Phytother Res, 2022. PMID 35624525

2022 / Randomized controlled parallel-group trial

Beginning complementary feeding with vegetables only increased vegetable intake and acceptance at 9 months compared to feeding both fruits and vegetables.

In a randomized trial, 117 infants were assigned to receive either vegetables only (n = 61) or a mix of fruits and vegetables (n = 56) for the first 4 weeks of complementary feeding. At 9 months of age, veg-only infants consumed significantly more broccoli [mean difference: 11.83 g (95% CI: 0.82, 22.84), P = 0.036] and spinach [mean difference: 10.19 g (95% CI: 0.50, 19.87), P = 0.039] than controls. Veg-only infants also had higher total vegetable intake (86.3 g vs. 67.5 g, P = 0.042) and showed greater acceptance and faster eating rates for target vegetables, while pear intake and acceptance were comparable. Introducing vegetables first was not associated with iron status at 9 months.

Rapson JP, von Hurst PR, Hetherington MM, et al. Am J Clin Nutr, 2022. PMID 35679432

2022 / Uncontrolled interventional program evaluation

A 15-day whole-food plant-based program significantly reduced weight, blood pressure, cholesterol, LDL, and fasting blood sugar.

Participants enrolled in a 15-day Jumpstart program were instructed to consume an Esselstyn-compliant, whole-food plant-based diet of vegetables, fruits, whole grains, and legumes. Among 389 participants, average weight loss was 5.8 pounds (7.3 for BMI >30), systolic blood pressure dropped by 6.8 points (16.8 for baseline >140), cholesterol decreased by 26 points (44 for baseline >200), LDL dropped by 19 points (33 for baseline >100), and fasting blood sugar fell by 5.1 points (28.4 for those starting in the diabetic range). All reported comparisons achieved statistical significance (P < .005 for fasting blood sugar and P < .001 for all others).

Friedman SM, Barnett CH, Franki R, et al. Am J Lifestyle Med, 2022. PMID 35706593

2022 / Randomized controlled trial

Performing kind acts for others over 4 weeks significantly reduced stress-related CTRA immune gene expression compared to controls.

In a randomized controlled trial, 182 community adults were assigned to perform three kind acts for others, three kind acts for themselves, or list daily activities (control) one day per week for 4 weeks. CTRA gene expression was assessed via RNA sequencing of dried blood spots at baseline and 5 weeks later. Participants randomized to perform kind acts for others demonstrated significant reductions in CTRA gene expression relative to controls. Participants randomized to kind acts for themselves showed significant reductions only among those who failed to adhere to the self-kindness protocol, while fully adherent participants showed no change and did not differ from controls.

Regan A, Fritz MM, Walsh LC, et al. Brain Behav Immun, 2022. PMID 35905861

2022 / Randomized controlled trial

At 5-year follow-up, differences in weight change between a commercial behavioural weight management programme and a brief intervention were not statistically significant.

The WRAP randomized controlled trial compared a brief intervention, a 12-week commercial open-group behavioural programme (WW), and a 52-week WW programme in adults with overweight and obesity. At 5 years, mean weight change from baseline was -0.46 kg (SD 8.31) for the brief intervention, -1.95 kg (9.55) for the 12-week group, and -2.67 kg (9.81) for the 52-week group. The adjusted difference in weight change was -1.76 kg (95% CI -3.68 to 0.17) between the 52-week programme and brief intervention, and -0.96 kg (-2.90 to 0.97) between the 12-week programme and brief intervention. Weight change differences between groups were not statistically significant, though simulations beyond 5 years suggested the 52-week programme would be the most cost-effective.

Ahern AL, Breeze P, Fusco F, et al. Lancet Public Health, 2022. PMID 36182236

2022 / Randomized, double-blind clinical trial

Turmeric combined with piperine reduced MDA and ferritin levels more effectively than turmeric alone in hemodialysis patients.

Hemodialysis patients aged 20-75 were randomized to receive 12 weeks of turmeric alone (3 g/day) or turmeric with piperine (3 g turmeric + 2 mg piperine/day). The turmeric/piperine group showed significantly greater reductions in MDA [-0.08(-0.14/0.01) nmol/mL vs -0.003(-0.10/0.26) nmol/mL, p=0.003] and ferritin [-193.80 ± 157.29 mg/mL vs 51.99 ± 293.25 mg/mL, p=0.018] compared to turmeric alone. Additionally, GPx activity decreased in the turmeric group (p=0.029), while no changes were observed for CAT, GR, or hs-CRP.

Freitas E Silva-Santana NC, Rodrigues HCN, Pereira Martins TF, et al. Free Radic Biol Med, 2022. PMID 36370961

2022 / Crossover trial

Substituting plant-based mince for beef mince reduced lunch pasta intake by 586 kJ without increasing subsequent buffet meal energy intake in healthy men.

In a crossover study, 24 healthy adult males consumed a pasta lunch with either plant-based or beef mince at separate visits. Participants consumed 586 kJ less of the plant-based mince pasta meal compared to the beef mince meal (p < 0.05). Energy intake at a subsequent buffet meal and ratings of fullness, satiety, and satisfaction were not different between meals (p > 0.05). Post-prandial GLP-1 concentrations were lower after the plant-based meal (p < 0.05), while insulin and leptin showed no differences.

Muhlhausler BS, Belobrajdic D, Wymond B, et al. Nutrients, 2022. PMID 36558487

2021 / Randomized crossover trial

Lemon juice lowered and delayed peak blood glucose after bread consumption in adults.

In a randomized crossover trial, healthy adults consumed 100 grams of bread paired with 250 milliliters of water, black tea, or lemon juice. Lemon juice reduced peak blood glucose concentration by 30% on average (p < 0.01) and delayed this peak by over 35 minutes (78 versus 41 minutes with water, p < 0.0001). Black tea had no effect on glycemic response, and neither beverage altered subsequent ad libitum energy intake.

Freitas D, Boué F, Benallaoua M, et al. Eur J Nutr, 2021. PMID 32201919

2021 / Phase 1 double-blind randomized placebo-controlled trial

In patients with alcohol-related cirrhosis, fecal microbiota transplant reduced alcohol craving and serious adverse events compared with placebo.

Twenty men with alcohol use disorder-related cirrhosis were randomized 1:1 to receive a single placebo or fecal microbiota transplant (FMT) enema from a donor enriched in Lachnospiraceae and Ruminococcaceae. At day 15, craving was reduced in 90% of the FMT group versus 30% in placebo (P = 0.02), accompanied by lower urinary ethylglucuronide/creatinine (P = 0.03), improved cognition and psychosocial quality of life, reduced IL-6, and increased microbial diversity and butyrate/isobutyrate. Over 6 months, patients with serious adverse events (SAEs) were significantly higher in placebo compared to FMT (8 vs. 2, P = 0.02), as were AUD-related SAEs (7 vs. 1, P = 0.02).

Bajaj JS, Gavis EA, Fagan A, et al. Hepatology, 2021. PMID 32750174

2021 / Randomized controlled trial

Autologous fecal microbiota transplantation collected during a green-Mediterranean diet phase significantly attenuated subsequent weight regain.

In the DIRECT PLUS trial, participants lost weight over 6 months on healthy guidelines, a Mediterranean diet, or a green-Mediterranean diet. Ninety participants provided fecal samples collected at month 6 and were randomized to receive capsules containing their own fecal microbiota (aFMT) or placebo until month 14. Across all participants, aFMT did not significantly reduce weight regain versus placebo (30.4% vs 40.6%, P = .28), but it significantly attenuated regain in the green-Mediterranean group (17.1% vs 50%, P = .02; P for interaction = .03). In this group, aFMT also reduced waist circumference gain (1.89 cm vs 5.05 cm, P = .01) and insulin rebound (P = .04).

Rinott E, Youngster I, Yaskolka Meir A, et al. Gastroenterology, 2021. PMID 32860791

2021 / Randomized, double-blind, three-arm pilot trial

Co-administering piperine at 5 mg or 25 mg with resveratrol did not significantly alter resveratrol pharmacokinetics in healthy volunteers.

In a randomized, double-blind, three-arm pilot study, 24 healthy participants were assigned to a single dose of 2.5 g resveratrol combined with 0 mg, 5 mg, or 25 mg of piperine. Serum levels were analyzed through 24 hours post-dose, and adverse events were monitored for 30 days. Pharmacokinetic values for resveratrol showed Cmax of 18.5 ± 16 ng/mL for resveratrol alone, 29 ± 29 ng/mL with 5 mg piperine, and 16 ± 13 ng/mL with 25 mg piperine, with no significant relationship between dose and pharmacokinetic values. All subjects tolerated the therapy with minimal to no toxicity.

Bailey HH, Johnson JJ, Lozar T, et al. Eur J Cancer Prev, 2021. PMID 32868637

2021 / Randomized, double-blind, placebo-controlled crossover trial

Resveratrol supplementation improved cognitive performance, cerebrovascular function, and insulin sensitivity in postmenopausal women.

In a 24-month crossover trial, 125 postmenopausal women aged 45-85 years took 75 mg trans-resveratrol or placebo twice daily for 12 months, followed by the alternative treatment for 12 months. Compared to placebo, resveratrol resulted in a significant 33% improvement in overall cognitive performance (Cohen's d = 0.170, P = 0.005). Resveratrol also improved resting mean cerebral blood flow velocity (d = 0.275, P = 0.001), cerebrovascular responsiveness to hypercapnia (d = 0.307, P = 0.027) and cognitive stimuli (d = 0.259, P = 0.032), fasting insulin (d = 0.174, P = 0.025), and insulin resistance index (d = 0.102, P = 0.034). Women aged 65 and older showed a relative improvement in verbal memory compared to those younger than 65 years.

Thaung Zaw JJ, Howe PR, Wong RH Clin Nutr, 2021. PMID 32900519

2021 / Parallel, double-blind, randomized, placebo-controlled trial

Celery seed supplementation for 6 weeks significantly improved total FSFI scores in women compared with placebo.

In a randomized, double-blind trial, 80 women received either 500 mg of celery seed or placebo 3 times a day for 6 weeks. At week 6, improvement in the total FSFI score was significantly greater with celery seed than placebo (P < 0.001). This increase was mainly driven by improvements in sexual desire (p < 0.001), arousal (p < 0.001), lubrication (p < 0.001), and pain (p = 0.033) domains. No serious side effects were observed in either group.

Hessami K, Rahnavard T, Hosseinkhani A, et al. J Ethnopharmacol, 2021. PMID 32971161

2021 / Randomized, double-blind, crossover trial

Anthocyanin-rich plum juice improved postprandial vascular function and reduced C-reactive protein after a high-fat high-energy meal in overweight older adults.

Sixteen overweight older adults consumed a high-fat high-energy meal with 250 mL of either anthocyanin-rich Queen Garnet Plum juice or control apricot juice in a randomized crossover trial. Compared to control, the anthocyanin arm had higher 2-hour postprandial flow-mediated dilatation (+1.14%, P = 0.019) and higher microvascular post-occlusive reactive hyperaemia (+0.10 perfusion units per mmHg, P = 0.049). C-reactive protein was lower at 4 hours postprandially in the anthocyanin arm (1.80 mg/L) compared with control (2.30 mg/L, P = 0.026). No significant postprandial differences were found for blood pressure, lipids, oxidative metabolites, or other inflammatory markers.

do Rosario VA, Chang C, Spencer J, et al. Clin Nutr, 2021. PMID 33071012

2021 / Three-group randomized crossover trial

A plant-based meal altered thalamus perfusion and stimulated greater active GLP-1 secretion than an energy-matched meat meal in men.

In a randomized crossover study, 60 men (with type 2 diabetes, overweight/obese, or healthy controls) consumed an energy- and macronutrient-matched vegan meal (V-meal) or conventional meat meal (M-meal). Thalamus perfusion decreased significantly after the M-meal in men with type 2 diabetes (p = 0.04) and overweight/obese men (p = 0.004), but decreased significantly after the V-meal in healthy controls (p < 0.001). Postprandial active GLP-1 secretion was higher after the V-meal compared with the M-meal by 42% in men with type 2 diabetes (p = 0.003) and by 41% in healthy controls (p = 0.002). Changes in thalamus perfusion after the meals correlated with changes in satiety (r = +0.68; p < 0.01).

Kahleova H, Tintera J, Thieme L, et al. Clin Nutr, 2021. PMID 33081982

2021 / Randomized, double-blind, placebo-controlled crossover trial

Oral semaglutide reduced daily ad libitum energy intake, improved appetite control, and decreased body weight and fat mass in people with type 2 diabetes.

A randomized, double-blind, placebo-controlled crossover trial evaluated 12 weeks of once-daily oral semaglutide versus placebo in 15 subjects with type 2 diabetes. In 13 evaluable subjects, total daily ad libitum energy intake was significantly lower by 38.9% with oral semaglutide versus placebo (estimated treatment difference: -5096.0 kJ; 95% CI -7000.0, -3192.1; P = .0001). Satiety, hunger, and overall appetite scores significantly favored semaglutide after a fat-rich breakfast, alongside fewer food cravings and better eating control. Mean body weight decreased by 2.7 kg with oral semaglutide compared to 0.1 kg with placebo, primarily due to loss of body fat mass.

Gibbons C, Blundell J, Tetens Hoff S, et al. Diabetes Obes Metab, 2021. PMID 33184979